Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug |
| gptkbp:CASNumber |
gptkb:129938-20-1
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
|
| gptkbp:developedBy |
gptkb:Roche
|
| gptkbp:hasMolecularFormula |
C34H34Cl2N4O4
|
| gptkbp:hasSMILES |
CN(C)C(=O)c1ccc(cc1)N2C(=O)N(C3=CC=CC=C3Cl)C4=CC=CC=C4ClC2
|
| gptkbp:hasUNII |
1Q1V1K4F1E
|
| https://www.w3.org/2000/01/rdf-schema#label |
RG-7112
|
| gptkbp:intendedUse |
anticancer agent
|
| gptkbp:IUPACName |
4-[(3R,4S)-4-(4-chlorophenyl)-3,4-dihydro-3-(4-chlorophenyl)-2(1H)-quinazolinone-1-yl]-N,N-dimethylbenzamide
|
| gptkbp:mechanismOfAction |
MDM2 inhibitor
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
25154816 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:RG7112
RO5045337 |
| gptkbp:target |
gptkb:MDM2_protein
|
| gptkbp:bfsParent |
gptkb:RG7112
|
| gptkbp:bfsLayer |
7
|